- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02048995
Neural and Visual Responses to Light in Bipolar Disorder: A Novel Putative Biomarker (LightEyeBD)
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
The study goal is to understand how the response to light therapy relates to changes in vision, brain function and improvement in bipolar symptoms. The aims are to investigate mood levels plus the eye and brain responses to visual contrast stimuli in healthy comparators (HC) and bipolar depressed patients.
Study Design and Methods. Overview. The investigators plan to enroll 18-50 year old adults with BD Type I or II and a current episode of major depression on stable-dosed antimanic drugs, and age and sex-matched HC - without mental disorders. Depressed patients with BD will be assigned randomly to receive active light therapy vs inactive comparator for 6 weeks. The investigators will examine responses to contrast stimuli from measures of visual evoked potentials and electro-retinography in HC and depressed bipolar patients before and after 6-weeks of daily midday light therapy. The investigators will assess repeated measures of mood symptom levels, attention and circadian rhythms.
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studie Locaties
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213
- Western Psychiatric Institute and Clinic
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Ages 18-50 years.
- DSM-IV BD Type I or II, current major depressive episode
- Stable-dosed antidepressant drug for 4 weeks or more only with concurrent antimanic drug.
- Controlled thyroid disease.
- Subjects with preexisting eye diseases will be included specific exceptions are described in the Exclusion Criteria.
- Able to provide informed consent.
- Stable minimum dose of antimanic drug for 4weeks or more.
- Stable unchanged psychotherapy for 16 weeks or more.
- Permitted drugs for sleep at low doses.
Exclusion Criteria:
- Certain specific eye diseases (retinal disease, untreated cataracts or macular degeneration)
- Photosensitizing drugs such as phenothiazines (chlorpromazine), antimalarial drugs, melatonin and hypericum.
- Acute psychosis (DSM-IV Criteria)
- Rapid cycling in the past 1 year
- Alcohol or substance abuse or dependence in the past 6 months.
- Current symptoms of hypomania or mania i.e. ManiaRatingScale=5
- Recent history of a suicide attempt (3 months) or active suicidal ideation (SIGH-ADS item H11=2 or more)
- Treatment with propranolol (Inderal), exogenous melatonin, chronic NSAIDS.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
|---|
|
Bipolar Depressed
Bipolar Depressed - are participants with Bipolar Disorder Type I or II and a current episode of major depression which is confirmed on the SCID interview
|
|
Healthy Comparator
Healthy Comparator - are participants without mental disorders, alcohol or substance disorders confirmed by the SCID-interview
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
visual evoked potentials (VEP) waveforms (mean amplitudes or latencies)
Tijdsspanne: Week 0 and Week 6
|
Visual Evoked Potential (VEP).
This is a test which is used to assess visual cortical responses.
The VEP recordings will be assessed at different contrast levels (80%, 16% and 7%) for the patient groups (BD vs HC).
To assess the change in visual cortical responses, we will compare differences in the VEP responses between Weeks 0 and 6 between the groups.
|
Week 0 and Week 6
|
|
Electroretinography (ERG) waveforms (mean amplitudes or latencies)
Tijdsspanne: Week 0 and Week 6
|
Electroretinogram (ERG).
This is a test which is used to assess electrical responses of the retina.
The ERG recordings will be assessed at different contrast levels (80%, 16% and 7%) for the patient groups (BD vs HC).
To assess the change in retinal responses, we will compare differences in ERG responses between Weeks 0 and 6 between the groups.
|
Week 0 and Week 6
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Dorothy Sit, M.D., University of Pittsburgh
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- PRO14010387
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .